Accellta develops customized processes, protocols and corresponding media for culturing stem cells in 3D suspension, under feeder-free, adherent-free conditions.
These solutions dramatically reduce the time and cost of stem cell manufacturing and enable the culturing of high quantities and densities of stem cells (>40 million cells/ml) of consistent, well-defined and homogeneous cell population.
The company enjoys a rich IP portfolio and has already completed several agreements with multi-national companies. The intellectual property assets of Accellta include a portfolio of patents pertaining to novel techniques and products, including:
- Pluripotent stem Cell culturing
- Growth media for feeder-free culturing of hPSC
- Stem Cell expansion in suspension
- Stem Cell culturing as single-cells in bioreactors
- Stem-Cell controlled differentiation
- Medium formulation
- Human foreskin-derived feeder cells
The company regularly partners with biopharma and cell research companies to developing custom-made solutions for pluripotent stem cells and stem cell-derived differentiated cells, such as neurons, cardiomyocytes and hepatocytes for research, drug screening, drug development and clinical trials. The company is always interested in establishing new dialogues.